Renaissance Technologies’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-602,100
| Closed | -$6M | – | 3697 |
|
|
2025
Q2 | $6M | Sell |
602,100
-43,500
| -7% | -$350K | 0.01% | 1404 |
|
|
2025
Q1 | $3.85M | Sell |
645,600
-191,600
| -23% | -$1.41M | 0.01% | 1581 |
|
|
2024
Q4 | $6.43M | Buy |
837,200
+300,800
| +56% | +$2.58M | 0.01% | 1283 |
|
|
2024
Q3 | $5.48M | Sell |
536,400
-23,200
| -4% | -$354K | 0.01% | 1387 |
|
|
2024
Q2 | $8.3M | Sell |
559,600
-157,700
| -22% | -$2.26M | 0.01% | 1030 |
|
|
2024
Q1 | $9.78M | Buy |
717,300
+18,400
| +3% | +$200K | 0.02% | 997 |
|
|
2023
Q4 | $7.65M | Buy |
698,900
+304,900
| +77% | +$3.02M | 0.01% | 1072 |
|
|
2023
Q3 | $4.31M | Sell |
394,000
-19,200
| -5% | -$246K | 0.01% | 1398 |
|
|
2023
Q2 | $5.47M | Buy |
413,200
+83,300
| +25% | +$1.19M | 0.01% | 1384 |
|
|
2023
Q1 | $4.49M | Buy |
329,900
+12,800
| +4% | +$229K | 0.01% | 1536 |
|
|
2022
Q4 | $6.19M | Sell |
317,100
-75,800
| -19% | -$1.48M | 0.01% | 1381 |
|
|
2022
Q3 | $7.49M | Buy |
392,900
+60,600
| +18% | +$1.4M | 0.01% | 1190 |
|
|
2022
Q2 | $6.84M | Buy |
332,300
+198,100
| +148% | +$4.7M | 0.01% | 1332 |
|
|
2022
Q1 | $4.32M | Buy |
134,200
+101,100
| +305% | +$3.67M | 0.01% | 1704 |
|
|
2021
Q4 | $1.54M | Buy |
+33,100
| New | +$1.1M | ﹤0.01% | 2354 |
|
Other funds holding ITOS
Renaissance Technologies's ITOS Position: Q3 2025 in Review
Renaissance Technologies sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 602,100 shares — an estimated $6M sold.
Renaissance Technologies first reported a position in ITOS in Q4 2021 and held it in 15 quarters. The position peaked at $9.78M in Q1 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Renaissance Technologies reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Renaissance Technologies sold 602,100 iTeos Therapeutics shares in Q3 2025, an estimated $6M.
- Renaissance Technologies first reported a position in iTeos Therapeutics in Q4 2021 and held it in 15 quarters.
- Renaissance Technologies's iTeos Therapeutics position peaked at $9.78M in Q1 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.